10x Genomics (NASDAQ:TXG) Beats Q1 Estimates But Falls as Revenue Shrinks Year-Over-Year

Endpoints NewsAstellas touts data from early test of stem cell-derived eye therapy

10x Genomics News10x Genomics (NASDAQ:TXG) Beats Q1 Estimates But Falls as Revenue Shrinks Year-Over-Year - ChartMill

10x Genomics News10x Genomics: Q1 Earnings Snapshot - KTVB

10x Genomics Blog10x Genomics’s (NASDAQ:TXG) Q1 CY2026: Beats On Revenue But Stock Drops - StockStory

10x Genomics Blog10x Genomics Reports First Quarter 2026 Financial Results - PR Newswire

10x Genomics BlogQ1 2026: 10x Genomics (NASDAQ: TXG) narrows loss, launches Atera - Stock Titan

BioPharma DiveSarepta tumbles as its gene therapy sales decline further

Clinical OMICsReduced Glaucoma Risk Connected to Migraine Medication Use

ScienceIn the remote Amazon, locals are saving a giant fish—and helping their villages

Clinical OMICsBroader Immune Targeting Increases Immunotherapy Benefit in Colorectal Cancer

Clinical OMICsAutism Screening Proposed for Children with Epilepsy

Clinical OMICsImmune Mapping Links Sex-Specific Genetics to Autoimmune Disease